Abstract
Left ventricular assist devices have been proven to be superior to medical therapy for advanced heart failure patients awaiting heart transplantation and viable alternatives to transplantation for destination therapy patients. Improvements in the design of ventricular assist devices have been rewarded by a decrease in adverse events and an increase in survival. Despite significant progress, even the latest generation left ventricular assist devices are burdened by a significant long-term adverse events profile that will increasingly challenge physicians as patients survive longer on implantable mechanical circulatory support. In this review, we analyze the impact of long-term adverse events on clinical outcomes in the major trials of continuous flow left ventricular assist devices. We discuss several of the more pertinent and interesting adverse events, examine their potential causes, and explore their future implications.
Original language | English (US) |
---|---|
Pages (from-to) | 89-100 |
Number of pages | 12 |
Journal | Current heart failure reports |
Volume | 10 |
Issue number | 1 |
DOIs | |
State | Published - Mar 2013 |
Keywords
- Adverse events
- Aortic insufficiency
- Continuous-flow
- Device malfunction
- Gastrointestinal bleeding
- Infection
- Left ventricular assist device(s)
- Pump thrombosis
- Stroke
ASJC Scopus subject areas
- Emergency Medicine
- Cardiology and Cardiovascular Medicine
- Physiology (medical)